Table III.
Change in soluble biomarker levels after 3 months of simvastatin treatment
| Biomarker | Baseline | Simvastastin treatment | % change | P-value |
|---|---|---|---|---|
| NOx (μM) | 27.5 (15.4, 34.6) | 28.2 (22.1, 36.0) | +2.5 | 0.40 |
| hs-CRP (mg/l) | 1.90 (1.70, 9.90) | 1.20 (0.90, 2.30) | −37 | 0.003 |
| sE-selectin (ng/ml) | 302.3 (132.3, 542.5) | 273.2 (114.5, 417.4) | −10 | 0.01 |
| sP-selectin (ng/ml) | 474.5 (304.9, 705.9) | 360.5 (269.8, 635.1) | −24 | 0.32 |
| sVEGF (ng/ml) | 122.3 (83.0, 195.0) | 98.3 (81.8, 163.8) | −20 | 0.01 |
| sICAM-1 (ng/ml) | 511.6 (381.3, 631.9) | 428.0 (361.6, 629.2) | −16 | 0.02 |
| sICAM-3 (ng/ml) | 154.2 (86.7, 176.8) | 128.8 (76, 156) | −16 | 0.02 |
| sVCAM-1 (ng/ml) | 992.4 (796.8, 1778) | 903.6 (706.8, 1664) | −9 | 0.12 |
Values are expressed as median and 25–75% interquartile range
hs-CRP, high sensitivity C-reactive protein; NOx, nitrite/nitrate; sE-selectin, soluble E-selectinsICAM-1, -3, soluble intercellular adhesion molecule 1, 3; sP-selectin, soluble P-selectin; sVCAM-1, vascular cell adhesion molecule 1; sVEGF, soluble vascular endothelial growth factor.